Ritgen M - Search Results

1

MRD Detection in B-Cell Non-Hodgkin Lymphomas Using Ig Gene Rearrangements and Chromosomal Translocations as Targets for Real-Time Quantitative PCR.

Pott C, Brüggemann M, Ritgen M, van der Velden VHJ, van Dongen JJM, Kneba M. Pott C, et al. Among authors: ritgen m. Methods Mol Biol. 2019;1956:199-228. doi: 10.1007/978-1-4939-9151-8_9. Methods Mol Biol. 2019. PMID: 30779036

2

The role of trephine bone marrow biopsies in the era of measurable residual disease-Results from the CLL10 trial of the German CLL Study Group (GCLLSG).

Kutsch N, Robrecht S, Fink A, Lange E, Weide R, Kiehl MG, Sökler M, Schlag R, Vehling-Kaiser U, Köchling G, Plöger C, Gregor M, Plesner T, Clausen MR, Oschlies I, Ritgen M, Herling M, Fischer K, Döhner H, Wendtner CM, Kreuzer KA, Stilgenbauer S, Hallek M, Böttcher S, Klapper W, Eichhorst B. Kutsch N, et al. Among authors: ritgen m. Hemasphere. 2024 Jul 24;8(7):e126. doi: 10.1002/hem3.126. eCollection 2024 Jul. Hemasphere. 2024. PMID: 39050548 Free PMC article. No abstract available.

3

Tislelizumab plus zanubrutinib for Richter transformation: the phase 2 RT1 trial.

Al-Sawaf O, Ligtvoet R, Robrecht S, Stumpf J, Fink AM, Tausch E, Schneider C, Boettcher S, Mikusko M, Ritgen M, Schetelig J, von Tresckow J, Vehling-Kaiser U, Gaska T, Wendtner CM, Chapuy B, Fischer K, Kreuzer KA, Stilgenbauer S, Staber P, Niemann C, Hallek M, Eichhorst B. Al-Sawaf O, et al. Among authors: ritgen m. Nat Med. 2024 Jan;30(1):240-248. doi: 10.1038/s41591-023-02722-9. Epub 2023 Dec 9. Nat Med. 2024. PMID: 38071379 Free PMC article. Clinical Trial.

4

Efficacy and safety of obinutuzumab combined with fludarabine and cyclophosphamide (FCG) or bendamustine (BG) in relapsed or refractory CLL patients followed by maintenance therapy with obinutuzumab for responding patients.

Kutsch N, Holmes EE, Robrecht S, Schüler G, Vehling-Kaiser U, Decker T, Müller-Hagen S, Heinisch K, Böttcher S, Ritgen M, Kreuzer KA, Stilgenbauer S, Fink AM, Fischer K, Eichhorst B, Hallek M, Wendtner CM. Kutsch N, et al. Among authors: ritgen m. Leuk Lymphoma. 2023 Feb;64(2):478-482. doi: 10.1080/10428194.2022.2148210. Epub 2022 Nov 24. Leuk Lymphoma. 2023. PMID: 36423347 No abstract available.

5

Unmutated immunoglobulin variable heavy-chain gene status remains an adverse prognostic factor after autologous stem cell transplantation for chronic lymphocytic leukemia.

Ritgen M, Lange A, Stilgenbauer S, Dohner H, Bretscher C, Bosse H, Stuhr A, Kneba M, Dreger P. Ritgen M, et al. Blood. 2003 Mar 1;101(5):2049-53. doi: 10.1182/blood-2002-06-1744. Epub 2002 Oct 31. Blood. 2003. PMID: 12411304 Free article.

6

The prognostic impact of autologous stem cell transplantation in patients with chronic lymphocytic leukemia: a risk-matched analysis based on the VH gene mutational status.

Dreger P, Stilgenbauer S, Benner A, Ritgen M, Kröber A, Kneba M, Schmitz N, Döhner H. Dreger P, et al. Among authors: ritgen m. Blood. 2004 Apr 1;103(7):2850-8. doi: 10.1182/blood-2003-05-1549. Epub 2003 Dec 11. Blood. 2004. PMID: 14670929 Free article.

7

Significance of minimal residual disease in lymphoid malignancies.

Brüggemann M, Pott C, Ritgen M, Kneba M. Brüggemann M, et al. Among authors: ritgen m. Acta Haematol. 2004;112(1-2):111-9. doi: 10.1159/000077566. Acta Haematol. 2004. PMID: 15179011 Review.

8

Graft-versus-leukemia activity may overcome therapeutic resistance of chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene status: implications of minimal residual disease measurement with quantitative PCR.

Ritgen M, Stilgenbauer S, von Neuhoff N, Humpe A, Brüggemann M, Pott C, Raff T, Kröber A, Bunjes D, Schlenk R, Schmitz N, Döhner H, Kneba M, Dreger P. Ritgen M, et al. Blood. 2004 Oct 15;104(8):2600-2. doi: 10.1182/blood-2003-12-4321. Epub 2004 Jun 17. Blood. 2004. PMID: 15205268 Free article. Clinical Trial.

9

Blastoid variant of mantle cell lymphoma: late progression from classical mantle cell lymphoma and quantitation of minimal residual disease.

Pott C, Schrader C, Brüggemann M, Ritgen M, Harder L, Raff T, Tiemann M, Dreger P, Kneba M. Pott C, et al. Among authors: ritgen m. Eur J Haematol. 2005 Apr;74(4):353-8. doi: 10.1111/j.1600-0609.2005.00409.x. Eur J Haematol. 2005. PMID: 15777349

10

Flow cytometric assay for determination of FcgammaRIIIA-158 V/F polymorphism.

Böttcher S, Ritgen M, Brüggemann M, Raff T, Lüschen S, Humpe A, Kneba M, Pott C. Böttcher S, et al. Among authors: ritgen m. J Immunol Methods. 2005 Nov 30;306(1-2):128-36. doi: 10.1016/j.jim.2005.08.004. Epub 2005 Sep 8. J Immunol Methods. 2005. PMID: 16181633

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

115 results

Search Page

Filters